>>>   Click for Diagenode’s approach to COVID-19

The JMJD3 Histone Demethylase and the EZH2 Histone Methyltransferase in Prostate Cancer

Daures M, Ngollo M, Judes G, Rifaï K, Kemeny JL, Penault-Llorca F, Bignon YJ, Guy L, Bernard-Gallon D

Prostate cancer is themost common cancer in men. It has been clearly established that genetic and epigenetic alterations of histone 3 lysine 27 trimethylation (H3K27me3) are common events in prostate cancer. This mark is deregulated in prostate cancer (Ngollo et al., 2014). Furthermore, H3K27me3 levels are determined by the balance between activities of histone methyltransferase EZH2 (enhancer of zeste homolog 2) and histone demethylase JMJD3 (jumonji domain containing 3). It is well known that EZH2 is upregulated in prostate cancer (Varambally et al., 2002) but only one study has shown overexpression of JMJD3 at the protein level in prostate cancer (Xiang et al., 2007). 
Here, the analysis of JMJD3 and EZH2 were performed at mRNA and protein levels in prostate cancer cell lines (LNCaP and PC-3), normal cell line (PWR-1E), and as well as prostate biopsies.


Share this article

February, 2016


Products used in this publication

  • Antibody ChIP-seq grade icon
    EZH2 Antibody - ChIP-seq Grade
  • Antibody ChIP-seq grade icon
    H3K27me3 Antibody - ChIP-seq Grade
  • RFX5-polyclonal-antibody-diagenode
    Rabbit IgG

       Site map   |   Contact us   |   Conditions of sales   |   Conditions of purchase   |   Privacy policy   |   Diagenode Diagnostics